LOGIN  |  REGISTER
Astria Therapeutics
Recursion

Zynex Sets Second Quarter 2024 Earnings Call

July 17, 2024 | Last Trade: US$7.86 0.04 0.51

ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2024.  Financial results will be issued in a press release prior to the call.

Zynex management will host the conference call, followed by a question and answer session.

Date: Thursday, July 25, 2024
Time: 4:15 PM Eastern Time (2:15 PM Mountain Time)
U.S. & Canada dial-in number: 800-930-7718
International number: 646-394-9830
Webcast: 2Q 2024 Webcast Link

The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB